Exelixis Inc reports results for the quarter ended June 30 - Earnings Summary
28/07/2025 22:02
Exelixis Inc EXEL.OQ reported quarterly adjusted earnings of 65 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 77 cents. The mean expectation of twenty analysts for the quarter was for earnings of 56 cents per share. Wall Street expected results to range from 42 cents to 65 cents per share. Revenue fell 10.8% to $568.26 million from a year ago; analysts expected $574.45 million. Exelixis Inc's reported EPS for the quarter was 65 cents. The company reported quarterly net income of $184.85 million. Exelixis Inc shares had risen by 3.5% this quarter and gained 36.9% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 20.8% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Exelixis Inc is $46.00, about 0.9% above its last closing price of $45.60 This summary was machine generated from LSEG data July 28 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | 0.56 | 0.65 | Beat |
| Mar. 31 2025 | 0.36 | 0.55 | Beat |
| Dec. 31 2024 | 0.43 | 0.48 | Beat |
| Sep. 30 2024 | 0.35 | 0.40 | Beat |